TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN

AC T01978 XX ID T01978 XX DT 29.11.1996 (created); hiwi. DT 27.03.2015 (updated); asv. CO Copyright (C), QIAGEN. XX FA JunD XX SY AP-1; jun D proto-oncogene; Jun-D; JUND; TRANSCRIPTION FACTOR JUN-D. XX OS human, Homo sapiens OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; primates XX GE G006330 JUND; HGNC: JUND. XX CL C0008; bZIP; XX SF relatively poor sequence conservation with human JunD [3]; SF a large part of the protein is required for full trans-activation, no small activating domain can be defined [3]; XX CP human endometrium from proliferative and secretory phases of the menstrual cycle and human decidua from early pregnancy [7]. XX FF activator with decreasing activity at high concentrations [3]; FF some spontaneous mutants may reveal enhanced trans-activation capability in combination with Fra-2 [4]; FF no inhibition of myogenic effects of MyoD or myogenin [1]; FF quickly enhanced expression within 60 min after TPA administration [2]; XX IN T15204 brca1; Mammalia. IN T01113 Elf-1; human, Homo sapiens. IN T01443 Nrf2; human, Homo sapiens. IN T30231 SIRT1-isoform1; human, Homo sapiens. XX MX M00517 V$AP1_01. MX M00924 V$AP1_Q2_01. MX M00926 V$AP1_Q4_01. MX M00925 V$AP1_Q6_01. MX M04681 V$JUND_01. MX M04776 V$JUND_02. MX M04803 V$JUND_03. MX M07104 V$JUND_04. MX M07105 V$JUND_05. MX M08934 V$JUND_06. MX M08935 V$JUND_07. MX M03552 V$JUND_Q6. XX BS R66333. BS R64299. BS R60543. BS R70646. BS R70685. BS R70687. BS R37581. BS R30618. BS R04348. BS R25298. BS R36995. BS R61970. BS R26709. BS R61832. BS R20982. BS R29738. BS R14540. BS R22557. BS R22542. BS R39947. BS R39854. BS R35816. BS R26802. BS R31706. BS R31708. BS R41737. BS R28548. BS R29689. BS R29092. BS R29093. BS R30620. BS R30939. BS R14544. BS R25018. BS R26674. BS R39833. BS R31611. BS R14724. BS R14725. BS R26758. BS R39281. BS R59836. BS R26793. BS R09882. BS R34900. BS R31188. BS R39889. BS R32816. BS R22860. BS R56920. BS R60863. BS R34120. BS R36611. BS R08494. BS R25195. BS R38461. BS R27962. BS R13178. BS R14478. BS R14480. BS R19623. BS R19624. BS R21760. BS R21763. BS R21747. BS R31592. BS R34765. BS R31616. BS R33593. BS R05017. BS R05020. XX DR TRANSPATH: MO000007834. DR UniProtKB: P17535; XX RN [1]; RE0003225. RX PUBMED: 1313772. RA Li L., Chambard J. C., Karin M., Olson E. N. RT Fos and Jun repress transcriptional activation by myogenin and MyoD: the amino terminus of Jun can mediate repression RL Genes Dev. 6:676-689 (1992). RN [2]; RE0004784. RX PUBMED: 2112242. RA Nomura N., Ide M., Sasamoto S., Matsui M., Date T., Ishizaki R. RT Isolation of human cDNA clones of jun-related genes, jun-B and jun-D RL Nucleic Acids Res. 18:3047-3048 (1990). RN [3]; RE0004786. RX PUBMED: 1903194. RA Berger I., Shaul Y. RT Structure and function of human jun-D RL Oncogene 6:561-566 (1991). RN [4]; RE0004788. RX PUBMED: 8415709. RA Kameda T., Akahori A., Sonobe M. H., Suzuki T., Endo T., Iba H. RT JunD mutants with spontaneously acquired transforming potential have enhanced transactivating activity in combination with Fra-2 RL Proc. Natl. Acad. Sci. USA 90:9369-9373 (1993). RN [5]; RE0013940. RX PUBMED: 10454570. RA Cirillo G., Casalino L., Vallone D., Caracciolo A., De Cesare D., Verde P. RT Role of distinct mitogen-activated protein kinase pathways and cooperation between Ets-2, ATF-2, and Jun family members in human urokinase-type plasminogen activator gene induction by interleukin-1 and tetradecanoyl phorbol acetate RL Mol. Cell. Biol. 19:6340-6252 (1999). RN [6]; RE0016689. RX PUBMED: 7648395. RA Bassuk A. G., Leiden J. M. RT A direct physical association between ETS and AP-1 transcription factors in normal human T cells. RL Immunity 3:223-237 (1995). RN [7]; RE0034082. RX PUBMED: 11266514. RA Watanabe K., Kessler C. A., Bachurski C. J., Kanda Y., Richardson B. D., Stanek J., Handwerger S., Brar A. K. RT Identification of a decidua-specific enhancer on the human prolactin gene with two critical activator protein 1 (AP-1) binding sites. RL Mol. Endocrinol. 15:638-53 (2001). RN [8]; RE0048037. RX PUBMED: 12080089. RA Hu Y. F., Li R. RT JunB potentiates function of BRCA1 activation domain 1 (AD1) through a coiled-coil-mediated interaction. RL Genes Dev. 16:1509-1517 (2002). RN [9]; RE0055188. RX PUBMED: 17921324. RA Cortez D. M., Feldman M. D., Mummidi S., Valente A. J., Steffensen B., Vincenti M., Barnes J. L., Chandrasekar B. RT IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta, NF-kappaB, and AP-1 activation. RL Am. J. Physiol. Heart Circ. Physiol. 293:H3356-65 (2007). RN [10]; RE0066649. RX PUBMED: 16984917. RA Byun H. J., Hong I. K., Kim E., Jin Y. J., Jeoung D. I., Hahn J. H., Kim Y. M., Park S. H., Lee H. RT A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. RL J. Biol. Chem. 281:34833-34847 (2006). RN [11]; RE0066800. RX PUBMED: 20220142. RA Por E., Byun H. J., Lee E. J., Lim J. H., Jung S. Y., Park I., Kim Y. M., Jeoung D. I., Lee H. RT The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F-dependent manner. RL J. Biol. Chem. 285:14475-14485 (2010). XX //